Could an antifungal drug boost breast cancer treatment?

NCT ID NCT06802757

First seen Feb 25, 2026 · Last updated May 06, 2026 · Updated 9 times

Summary

This study tests whether adding the antifungal drug posaconazole to standard immunotherapy and chemotherapy can help more women with triple-negative breast cancer achieve a complete response before surgery. About 72 women with early-stage, high-risk breast cancer will participate. The goal is to see if this combination can shrink tumors more effectively than current treatment alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Breast Cancer Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences

    RECRUITING

    Jinan, Shandong, 250117, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.